SABCS 2018 — Oxybutynin reduces hot-flash frequency and interference with QoL


  • Tara Haelle
  • Univadis
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Oxybutynin significantly improves hot-flash frequency and severity and QoL, according to data from ACCRU study SC-1603.

Why this matters

  • Hot flashes are associated with decreased QoL and premature discontinuation of breast cancer treatment.
  • Oxybutynin does not interfere with the metabolism of tamoxifen.

Study design

  • 150 women experiencing hot flashes ≥28 times a week >30 days were randomly assigned to receive twice-daily 2.5 mg (n=51) or 5 mg (n=50) oral oxybutynin or placebo for 6 weeks.
    • 62% were receiving tamoxifen or an aromatase inhibitor.
  • Weekly hot flash diary, Hot Flash Related Daily Interference Scale (HFRDIS), and symptom experience questionnaire.

Key results

  • 113 patients had postbaseline data compared with placebo (n=38): 
    • Patients receiving 2.5 mg (n=40) had lower mean hot flash score (−10 vs −5.1; P=.003) and greater reduction in average weekly hot flashes (−4.6 vs −2.3; P=.002).
    • Patients receiving 5 mg (n=35) had lower mean hot flash score (−16.2 vs −5.1; P<.001 and greater reduction in average weekly hot flashes vs p>
  • HFRDIS showed improvement related to work, social and leisure activities, sleep, relations, and overall QoL with 2.5 mg, plus life enjoyment and mood with 5 mg. 
  • Significant adverse effects included dry mouth, abdominal pain, and difficulty urinating at both doses, and dry eyes, confusion, diarrhea, and headaches with 5 mg.
  • Funding: Breast Cancer Research Foundation.
  • Dr. Leon-Ferre reported receiving travel support from Immunomedics.

Limitations 

  • No data on long-term toxicity.